Acknowledgements
leukemia, Acute Myeloid Leukemia
LEUKEMIA, ACUTE MYELOID LEUKEMIA, AML, NPM1 MUTATION
This work was supported by grant 01KG1004 [AMLSG 15-10: Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All Trans Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and NPM1 Mutation] from the German Bundesministerium für Bildung und Forschung (BMBF). We are also grateful to all members of the German-Austrian AML Study Group (AMLSG) for providing leukemia specimens and clinical data.